Search Results for: FORMULATION DEVELOPMENT TECHNOLOGY A Novel
Articles
Exavir Therapeutics Announces Preclinical Data for Ultra-Long-Acting Dolutegravir Prodrug XVIR-120 June 9, 2022
Exavir Therapeutics recently announced the publication of preclinical data for XVIR-120, an investigational agent being developed as a long-acting injectable antiviral for HIV….
Catalent & MigVax Sign Agreement to Develop an Orally Disintegrating Freeze-Dried Tablet Vaccine Against COVID-19 June 7, 2022
Catalent and MigVax recently announced they have signed a development agreement to leverage Catalent’s proprietary Zydis Bio orally disintegrating tablet...Assembly Biosciences Initiates Phase 1b Clinical Trial Evaluating Next-Generation Core Inhibitor June 6, 2022
Assembly Biosciences, Inc. recently announced the initiation of a Phase 1b trial of its investigational next-generation, highly potent core inhibitor...Evonik Invests $220 Million to Build New Lipid Production Facility for mRNA-based Therapies in the US June 2, 2022
Evonik is building a new, highly flexible, global-scale production facility for pharmaceutical lipids in the US. The new plant at...Enteris BioPharma to Exhibit at CPhI North America 2022 May 9, 2022
Enteris BioPharma, Inc., a biotechnology company developing innovative drug products based on its proprietary delivery technologies, and a wholly owned...Hovione & JIXING Announce an Exclusive Global License Agreement for Ophthalmology Program May 9, 2022
Hovione, the leader in spray drying and particle engineering, recently announced an exclusive license agreement for a preclinical ophthalmology program, JX08, with….
SPECIAL FEATURE - PFS & Parenteral Drug Delivery: Self-Injection is Very Much the “New Normal” May 2, 2022
Contributor Cindy H. Dubin showcases how leading CDMOs and drug delivery developers are responding to current market trends to create ergonomic technologies that are patient friendly, easy to use, reduce needle anxiety, and feature improved packaging materials.
EXECUTIVE INTERVIEW - PCI Pharma Services: Broadening Our Biologics Footprint, Together May 2, 2022
Shawn Cain, SVP Development & Manufacturing at PCI Pharma Services, discusses the recent acquisition, the opportunities this presents to Biopharma companies, and the current trends in the sterile fill-finish industry.
Caladrius Biosciences & Cend Therapeutics Announce Definitive Merger Agreement April 27, 2022
Caladrius Biosciences, Inc. and Cend Therapeutics, Inc. recently announced the companies have entered into a definitive merger agreement under which Cend will merge with a wholly owned subsidiary of….
Blacktrace Launches Particle Works – The New Dedicated Particle Engineering Brand April 22, 2022
Particle Works’ game-changing particle engineering platforms are set to revolutionize the way customers discover, develop and scale-up particle production for a wide range of….
Blue Water Vaccines Presents New Data Supporting Universal Influenza Vaccine Candidate April 21, 2022
Blue Water Vaccines Inc. recently issued the below statement regarding its Form 8-K filed with the Securities and Exchange Commission...KemPharm Doses First Subject in Phase 1 Clinical Trial Evaluating Cardiovascular Safety of Serdexmethylphenidate April 19, 2022
KemPharm, Inc. recently announced the first subject has been dosed in a Phase 1 clinical trial designed to assess the...Daré Bioscience Initiates Phase 1/2 Clinical Study of DARE-HRT1 April 12, 2022
Daré Bioscience, Inc. recently announced the initiation of a Phase 1/2 clinical study of DARE-HRT1. DARE-HRT1 is a novel intravaginal...SPECIAL FEATURE - Excipients: Exciting Expansion & Innovation April 4, 2022
Contributor Cindy H. Dubin speaks with several companies and presents a unique look at how excipients are being used to support current and future innovative active pharmaceutical ingredients.
Rani Therapeutics Announces Initiation of Phase 1 Study for Osteoporosis March 23, 2022
Rani Therapeutics Holdings, Inc. recently announced the initiation of a Phase 1 study of RT-102, an oral formulation of the...Soligenix COVID-19 Vaccine Boosts Neutralizing Activity Against SARS-CoV-2, Including Delta & Omicron March 17, 2022
Soligenix, Inc.recently announced the results of a booster vaccination study using CiVax (heat stable COVID-19 subunit vaccine program) in non-human...SPECIAL FEATURE - Solubility & Bioavailability: Utilizing Enabling Technologies March 1, 2022
Contributor Cindy H. Dubin interviews several leading companies on how they are using innovative technologies, such as lipid nanoparticles to achieve a high drug loading, combining anti-solvent continuous crystallization with micro-mixing technology to control crystallization and reduce crystal size, and how a robotic capsule can improve bioavailability in the range of 47% to 78%.
Hovione & Zerion Pharma Announce Strategic Partnership February 22, 2022
Hovione recently announced a strategic partnership with Zerion Pharma to market and commercialize Dispersome, Zerion´s proprietary solubility enhancement….
Recipharm Announces Acquisition of Vibalogics & Arranta Bio February 18, 2022
Recipharm is continuing to build its service offerings in new biologic modalities through the acquisition of Vibalogics and Arranta Bio….
Evelo Biosciences Announces Highly Significant Reductions in Clinically Validated Inflammatory Cytokines in EDP1815 Phase 2 Psoriasis Trial February 7, 2022
Evelo Biosciences, Inc. recently announced the results of immunological biomarker analyses from its previously reported Phase 2 trial of orally-dosed...Company Profiles
Lyophilization Technology, Inc.
Lyophilization Technology, Inc. 30 Indian Drive Ivyland, PA 18974-1431 T: (215) 396-8373 F: (215) 396-8375 E: inquiry@lyo-t.com W: www.lyotechnology.com WHO...CycloLab Cyclodextrin Research & Development Ltd.
CycloLab Cyclodextrin Research & Development Ltd. E: commerce@cyclolab.hu W: cyclolab.hu LinkedIn: https://www.linkedin.com/company/10040240 For more than 30 years, Cyclolab Ltd. has been involved in...
